Urina de paciente internada em hospital fica com coloração roxa: entenda

Paciente apresentou sintomas da síndrome da urina roxa, observada pela primeira vez em 1978

Fonte: Urina de paciente internada em hospital fica com coloração roxa: entenda

Recurrent Cystitis? Drink More Water

Upping water intake lowered risk of urinary tract infection in randomized trial

Fonte: Recurrent Cystitis? Drink More Water

Tal como a vovó recomendava…

Cranberry não ajuda na prevenção de ITU’s recorrentes


Como diria o Chapolim Colorado, “suspeitei desde o princípio”.

Desculpem, mas não consegui o link, só o resumo.

Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study | Read by QxMD

BACKGROUND: Fosfomycin is increasingly called upon for the treatment of multi drug-resistant (MDR) organisms causing urinary tract infection (UTI). We reviewed oral fosfomycin use for UTI treatment in a large UK hospital. The primary goal was to audit our clinical practice against current national guidelines. Secondary aims were to identify factors associated with treatment failure, and to investigate the potential for using fosfomycin in patients with co-morbidities. METHODS: We retrospectively studied 75 adult patients with UTI who received 151 episodes of treatment with fosfomycin from March 2013 to June 2015. We collected clinical data from our electronic patient record, and microbiology data pre- and post- fosfomycin treatment. We recorded additional data for patients receiving prolonged courses in order to make a preliminary assessment of safety and efficacy. We also reviewed >18,000 urinary tract isolates of Escherichia coli and Klebsiella spp. processed by our laboratory over the final year of our study period to determine the prevalence of fosfomycin resistance. RESULTS: There was a significant increase in fosfomycin treatment episodes over the course of the study period. Co-morbidities were present in 71 % of patients. The majority had E. coli infection (69 %), of which 59 % were extended spectrum beta-lactamase (ESBL)-producers. Klebsiella infections were more likely than E. coli to fail treatment, and more likely to be reported as fosfomycin resistant in cases of relapse following treatment. There were no adverse events in five patients treated with prolonged fosfomycin. Among all urinary isolates collected over a year, fosfomycin resistance was documented in 1 % of E. coli vs. 19 % of Klebsiella spp. (p < 0.0001). CONCLUSIONS: We report an important role for oral fosfomycin for MDR UTI treatment in a UK hospital population, and based on the findings from this study, we present our own local guidelines for its use. We present preliminary data suggesting that fosfomycin is safe and effective for use in patients with complex comorbidities and over prolonged time periods, but may be less effective against Klebsiella than E. coli.

Fonte: Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study | Read by QxMD

Catheter-Associated UTI Prevention — NEJM

Quick Take Video Summary from The New England Journal of Medicine — Catheter-Associated UTI Prevention

Fonte: Catheter-Associated UTI Prevention — NEJM

Vídeo bacana do NEJM sobre prevenção de ITU em cateterização vesical. Infelizmente em inglês.